Telix Pharmaceuticals is trading 6.7% down now in pre-market at $11.03 after falling from its August 14 close of $11.82; no clear company-specific catalyst has been identified.
- Nasdaq futures are modestly positive, so broader market sentiment does not clearly explain the decline.
- Investors may be positioning cautiously ahead of Telix’s scheduled half-year results release on August 20, 2026.